INBUILD® Trial Efficacy (autoimmune ILD patients)
15/03/2023 | Author: Boehringer Ingelheim
Document ID: PC-SG-101828
EFFICACY
RELATED CONTENT
3:53
INBUILD® Trial Efficacy (RA-ILD Subgroup Analysis) by Dr E. Volkmann
![FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline](/sg/sites/default/files/styles/bi_gds_card_style/public/2023-12/PC-SG-101832.png)
FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline
![SGOFV2023COM||INBUILD® Trial Population and Baseline Medications](/sg/sites/default/files/styles/bi_gds_card_style/public/2023-12/INBUILD%C2%AE%20Trial%20Population%20and%20Baseline%20Medications.png)